NCT00477971 · REGISTRY CONDITION SEARCH

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE3
Status at capture: COMPLETED
Registry last update: 2016-05-17

RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Having an autologous stem cell transplant to replace the blood-forming cells destroyed by chemotherapy, allows higher doses of chemotherapy to be given so that more plasma cells are killed. By reducing the number of plasma cells, the disease may progress more slowly. It is not yet known whether combination chemotherapy is more effective than chemotherapy followed by an autologous stem cell transplant in treating primary systemic amyloidosis. PURPOSE: This randomized phase III trial is studying the side effects and how well giving low-dose melphalan together with dexamethasone works compared with high-dose melphalan followed by an autologous stem cell transplant in treating patients with primary systemic amyloidosis.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Hematologic Response Rate

→

outcome · POSTED

3 Year Overall Survival

→

outcome · POSTED

Organ Response to Treatment

→

outcome · POSTED

3-Year Progression Free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Histologically confirmed primary systemic amyloidosis * Amyloid light-chain (AL) disease * Monoclonal protein by immunoelectrophoresis or immunofixation of the serum or urine OR abnormal free light-chain ratio * The following amyloid syndromes\* are allowed: * Amyloid hepatomegaly * Cardiomyopathy * Proteinuria * Peripheral or autonomic neuropathy * Soft tissue involvement including the tongue, submandibular tissues, and vascular claudication * Diffuse interstitial pulmonary AL disease allowed if pulmonary function is adequate to allow safe transplantation NOTE: \*Presence of amyloid deposits in a plasmacytoma or in bone marrow vessels in an asymptomatic patient does not constitute an amyloid syndrome * No secondary or familial amyloidosis * No multiple myeloma with lytic or destructive bone lesions or myeloma cast nephropathy * No multiple myeloma with \> 30% plasma cells in the bone marrow * No amyloidosis manifested only by carpal tunnel syndrome or purpura PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Platelet count ≥ 100,000/mm³ * Bilirubin ≤ 2.0 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 6 times ULN * Creatinine ≤ 3.0 mg/dL * No NYHA class IV heart disease * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No uncontrolled infection * No HIV positivity PRIOR CONCURRENT THERAPY: * Prior alkylating agents, immunosuppressive drugs, or steroids allowed provided they were given for \< 1 month * Therapeutic steroid doses of ≤ 15 mg per day (or equivalent) allowed at discretion of physician * No concurrent participation in another clinical trial involving a pharmacologic agent
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive low-dose melphalan IV over 15-30 minutes on day 1 or orally once daily on days 1-7 and oral dexamethasone on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses. Study treatment beyond one year is not allowed.
intervention Names
Drug: dexamethasone
Drug: melphalan
label
Arm A
type
ACTIVE_COMPARATOR
description
Patients receive filgrastim (G-CSF) on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan IV over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.
intervention Names
Biological: filgrastim
Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation
label
Arm B
type
EXPERIMENTAL

interventions

arm Group Labels
Arm B
description
No administration information given
name
filgrastim
type
BIOLOGICAL
arm Group Labels
Arm A
description
Given orally
name
dexamethasone
type
DRUG
arm Group Labels
Arm A
Arm B
description
Given IV or orally
name
melphalan
type
DRUG
arm Group Labels
Arm B
description
Given on day 0
name
autologous hematopoietic stem cell transplantation
type
PROCEDURE

Study design

allocation

NON_RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 89
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Response that was confirmed on 2 consecutive evaluations during treatment. A hematologic response consisted of a Complete response, Very Good Partial Response or Partial Response. * Complete Response (CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and \<5% plasma cells in bone marrow. * Very Good Partial Response (VGPR): \>=90% reduction in serum M-component; Urine M-Component \<=100 mg per 24 hours. * Partial Response (PR): \>=50% reduction in serum M-component and/or Urine M-Component \>=90% reduction or \<200 mg per 24 hours; or \>=50% decrease in difference between involved and uninvolved FLC levels.
measure
Hematologic Response Rate
time Frame
10 years

secondary Outcomes

description
Percentage of patients who were alive at 3 years. The 3-year survival rate was estimated using the Kaplan Meier method.
measure
3 Year Overall Survival
time Frame
3 years
description
Organ response was evaluated on the basis of improvement of one or more affected organ; only one parameter was required to satisfy the criteria. Response needed to be maintained for a minimum of 3 months to be considered valid. Renal response required a 50% reduction in 24-hour urine protein excretion (at least 0.5 g/d) with stable creatinine. Cardiac response required one of \>= 2-mm reduction in the interventricular septal (IVS) thickness by echocardiogram, or improvement of ejection fraction by \>= 20%, or improvement by 2 NYHA classes without an increase in diuretic use. Hepatic response required either \>= 50% decrease in (or normalization of) an initially elevated alkaline phosphatase level or reduction in the size of the liver by at least 2 cm by radiographic determination. Gastrointestinal tract improvement was defined as normalization of a low serum carotene level, or reduction of diarrhea to \< 50% of previous movements/day, or decrease in fecal fat excretion by 50%.
measure
Organ Response to Treatment
time Frame
10 years

Full study description

brief Summary: RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Having an autologous stem cell transplant to replace the blood-forming cells destroyed by chemotherapy, allows higher doses of chemotherapy to be given so that more plasma cells are killed. By reducing the number of plasma cells, the disease may progress more slowly. It is not yet known whether combination chemotherapy is more effective than chemotherapy followed by an autologous stem cell transplant in treating primary systemic amyloidosis. PURPOSE: This randomized phase III trial is studying the side effects and how well giving low-dose melphalan together with dexamethasone works compared with high-dose melphalan followed by an autologous stem cell transplant in treating patients with primary systemic amyloidosis.
detailed Description: OBJECTIVES: Primary * Compare hematologic response rate in patients with primary systemic amyloidosis treated with conventional chemotherapy comprising low-dose melphalan and dexamethasone vs high-dose melphalan followed by autologous stem cell transplantation. * Compare the toxicity of these regimens in these patients. Secondary * Compare the overall and progression-free survival of patients treated with these regimens. * Compare the regression of organ involvement in patients treated with these regimens. * Compare the duration of response in patients treated with these regimens. * Correlate clonal burden and time to in vitro amyloid formation with clinical outcomes in patients treated with these regimens. * Compare quality of life of patients treated with these regimens. * Compare the information-seeking behavior in patients treated with these regimens. OUTLINE: This is a comprehensive cohort study comprising a randomized option and a nonrandomized option. Patients consenting to randomization are stratified by risk group (high vs low) and ECOG performance status (0-1 vs 2). They are then randomized to 1 of 2 treatment arms. Patients not consenting to randomization choose their treatment arm. * Arm I: Patients receive low-dose melphalan IV over 15-30 minutes on day 1 or orally once daily on days 1-7 and oral dexamethasone on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses in the absence of disease progression or unacceptable toxicity. * Arm II: Patients receive filgrastim (G-CSF) on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan IV over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0. Blood and bone marrow samples are collected at baseline. Samples are examined by PCR, cDNA, and nucleotide sequence analysis to determine VH and VL gene families and carrier status. Urine is collected at baseline and analyzed for light-chain protein levels by exclusion chromatography. Quality of life is assessed at baseline, at months 3, 9, and 12, at completion of study treatment, and then every 6 months for up to 5 years. After completion of study treatment, patients are followed every 6 months for up to 10 years.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-718e423f6a1d413447f2
requested nct id
NCT00477971
primary nct id
NCT00477971
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
041953f4438c5ee4bf793f40df83c23a33aedc759f057b4d4b7ef5695094f355
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-718e423f6a1d413447f2
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00477971
occurrences
context exact
NCT00477971
end
11
exact text
NCT00477971
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/970/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
4da4ae81bd46dfb7716596d62fa7e5de71fe7f6ae119a161b7b665893dcf0162
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice